Tyra Biosciences, Inc. financial data

Symbol
TYRA on Nasdaq
Industry
Pharmaceutical Preparations
Location
2656 State Street, Carlsbad, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.88K % -26%
Debt-to-equity 5.34 % +22.2%
Return On Equity -25.1 % -2.7%
Return On Assets -23.9 % -1.75%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50.6M shares +17.5%
Common Stock, Shares, Outstanding 52.9M shares +23.2%
Entity Public Float 267M USD +120%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 58.9M shares +37.3%
Weighted Average Number of Shares Outstanding, Diluted 58.9M shares +37.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 78.6M USD +50.4%
General and Administrative Expense 21.5M USD +25.9%
Operating Income (Loss) -100M USD -44.4%
Nonoperating Income (Expense) 16.4M USD +61.4%
Net Income (Loss) Attributable to Parent -83.7M USD -41.5%
Earnings Per Share, Basic -1.62 USD/shares -17.4%
Earnings Per Share, Diluted -1.62 USD/shares -17.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 104M USD -51.8%
Assets, Current 366M USD +62.8%
Property, Plant and Equipment, Net 1.79M USD +56%
Other Assets, Noncurrent 6.01M USD +12.4%
Assets 381M USD +59.7%
Accounts Payable, Current 1.17M USD -49.5%
Liabilities, Current 12.4M USD +21.9%
Operating Lease, Liability, Noncurrent 5.92M USD -0.74%
Other Liabilities, Noncurrent 11K USD -85.7%
Liabilities 18.3M USD +13.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.75M USD
Retained Earnings (Accumulated Deficit) -226M USD -59%
Stockholders' Equity Attributable to Parent 362M USD +63.1%
Liabilities and Equity 381M USD +59.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22M USD -124%
Net Cash Provided by (Used in) Financing Activities 200M USD +53175%
Net Cash Provided by (Used in) Investing Activities 18.1M USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 52.9M shares +22.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 196M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 105M USD -51.6%
Deferred Tax Assets, Valuation Allowance 40.9M USD +77.3%
Deferred Tax Assets, Gross 42.6M USD +79.2%
Operating Lease, Liability 6.32M USD +3.37%
Depreciation 400K USD +19%
Payments to Acquire Property, Plant, and Equipment 136K USD +232%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -82M USD -4.39%
Lessee, Operating Lease, Liability, to be Paid 8.9M USD -1.24%
Property, Plant and Equipment, Gross 2.97M USD +60.2%
Operating Lease, Liability, Current 398K USD +169%
Lessee, Operating Lease, Liability, to be Paid, Year Two 900K USD +8.83%
Lessee, Operating Lease, Liability, to be Paid, Year One 874K USD +21.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.59M USD -11%
Lessee, Operating Lease, Liability, to be Paid, Year Three 927K USD +8.8%
Deferred Tax Assets, Operating Loss Carryforwards 14.1M USD +21.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Unrecognized Tax Benefits 3.01M USD +91%
Lessee, Operating Lease, Liability, to be Paid, Year Four 955K USD +8.89%
Operating Lease, Payments 500K USD -37.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 122K USD +47%
Deferred Tax Assets, Net of Valuation Allowance 1.64M USD +144%
Share-based Payment Arrangement, Expense 20.3M USD +65.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%